Last reviewed · How we verify
SHR-A1811
SHR-A1811 is a small molecule targeting the molecular target.
SHR-A1811 is a small molecule targeting the molecular target. Used for Non-small cell lung cancer.
At a glance
| Generic name | SHR-A1811 |
|---|---|
| Also known as | Trastuzumab-rezetecan, Trastuzumab Rezetecan, T-DXh |
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Drug class | small molecule |
| Target | unknown |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
SHR-A1811 works by binding to the molecular target, which results in the desired therapeutic effect.
Approved indications
- Non-small cell lung cancer
Common side effects
- unknown
Key clinical trials
- SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC (PHASE2)
- Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer (PHASE2)
- The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis (PHASE2)
- Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer (PHASE2)
- Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver Metastases (PHASE2)
- A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer (PHASE3)
- SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study (PHASE2)
- Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SHR-A1811 CI brief — competitive landscape report
- SHR-A1811 updates RSS · CI watch RSS
- Jiangsu HengRui Medicine Co., Ltd. portfolio CI